Nivolumab Immunotherapy Preparation
Mixed nivolumab monoclonal antibody product for PD-1 inhibition in cancer immunotherapy. HTS 3002.14.0010 classification for bulk mixed immunological containing monoclonals for clinical trials. Includes sucrose stabilizer and buffer system.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If in retail packages over 25kg
Large retail packages have separate statistical suffix.
If hormones other than specified
Certain conjugates may classify under other hormones.
If mechano-therapy appliance reagent
Combination products with therapy devices use different headings.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• For clinical trial material, include IRB approval and protocol summaries
• Ensure GMP certification for manufacturing site; provide batch release docs
• Avoid retail packing to maintain bulk classification advantage
Related Products under HTS 3002.14.00.10
Rituximab Biosimilar Immunological Preparation
A mixed immunological product containing rituximab monoclonal antibodies used for treating non-Hodgkin lymphoma and rheumatoid arthritis. Classified under HTS 3002.14.0010 as it is an immunological product containing monoclonal antibodies, not put up in measured doses or retail packings. It consists of multiple components including the antibody and stabilizers for therapeutic use.
Trastuzumab Emtansine Mixture
Immunological preparation mixing trastuzumab monoclonal antibody with emtansine for HER2-positive breast cancer treatment. Falls under HTS 3002.14.0010 due to monoclonal antibody content in a mixed, non-retail bulk form for hospital use. Includes buffers and stabilizers as mixed components.
Pembrolizumab Bulk Immunological Product
Mixed preparation of pembrolizumab (Keytruda) monoclonal antibody for immunotherapy in melanoma and lung cancer. HTS 3002.14.0010 applies to this bulk mixed form containing the antibody with formulation excipients, not for retail. Used in clinical or manufacturing settings.
Bevacizumab Biosimilar Mixture
Bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. Classified in HTS 3002.14.0010 as a mixed monoclonal immunological product not in retail form. Contains antibody, surfactants, and buffers.
Infliximab Therapeutic Mixture
Mixed immunological preparation containing infliximab monoclonal antibodies for autoimmune diseases like Crohn's. HTS 3002.14.0010 for bulk mixed monoclonal products used in biotech manufacturing. Includes polysorbate and histidine buffers.
Adalimumab Reference Product Bulk
Bulk mixed form of adalimumab (Humira) monoclonal antibody for rheumatoid arthritis treatment. Falls under HTS 3002.14.0010 as mixed immunological product with monoclonal antibodies, supplied for further dilution. Not in measured retail doses.